The words, used properly
Most confusion in this category is vocabulary rather than biology. The treatment is botulinum toxin type A; the familiar name is one manufacturer’s brand, which is why this publication writes about the medicine rather than the brand and sets out its position on trade marks in its trade mark notice. Toxin and filler are not variants of one thing: they have different mechanisms, different durations, different risks and different reversibility, and a consultation that treats them as interchangeable has already gone wrong. Anti wrinkle injection is a marketing phrase rather than a clinical one, and it tells you nothing about which of the three groups is being proposed.
What the evidence supports, and where it stops
The mechanism of botulinum toxin is well established and its use in medicine long predates its cosmetic use; chronic migraine, for instance, is a licensed indication delivered to a defined protocol, which is a different proposition from a cosmetic appointment, as our report on toxin for migraine sets out. What is far less settled is the comparative question a patient actually asks: which product, which dose and which technique produces the better result in a given area. Trials in this field are commonly small, short, unblinded and assessed on appearance, and appearance endpoints are the easiest of all to flatter. Any effect is time limited and varies with the area, the dose and the individual, so duration quoted as a fixed number is a convenience rather than a finding.
Filler evidence has its own limit: the material behaves differently in different tissue planes, and a result reported for one area does not transfer to another. Most hyaluronic acid fillers can be broken down with hyaluronidase, which is a genuine safety advantage and not a reset button, as our piece on dissolving filler explains. Where a claim on this publication rests on thin evidence we say so rather than rounding it up; how to read the claims you will be shown is set out in reading injectable treatment claims.
What to ask before anything is injected
Five questions do most of the work. Who is the prescriber, and are they on a statutory register you can search yourself. Have they assessed you in person, rather than signing a prescription for somebody else to administer. Which product and what dose, recorded in your notes. What is the plan if something goes wrong, including who you reach out of hours and, for filler, whether hyaluronidase is on the premises. And what is included afterwards: a review appointment, or nothing. A clinic that answers all five without hesitation has told you most of what you need to know. Our consultation red flags checklist carries the longer version.
Where the United Kingdom rules sit
Botulinum toxin products are prescription only medicines under the Human Medicines Regulations 2012, so one lawfully reaches a patient only through a prescriber. That status also governs how the treatment may be promoted: the Advertising Standards Authority’s published advice states that botulinum toxin products cannot be advertised to the public under rule 12.12 of the CAP Code, and that in practice almost any reference to them in an advertisement is treated as promoting a prescription only medicine, hashtags included. That is why a clinic cannot lawfully advertise the brand or run an offer on it, and why advertising that does so is worth noticing. Dermal fillers are not prescription only medicines, which is why the advertising rules fall differently on them and why the gap between how the two are marketed is so wide. What the words clinic and practitioner do and do not guarantee in law is covered in what aesthetic clinic actually means in UK law and indexed in our UK clinic law clarity index. Rules and regulatory positions change, so check the current position with the body that holds it rather than with us.
